{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:55:38Z","timestamp":1793141738285,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2042022dx0003"],"award-info":[{"award-number":["2042022dx0003"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"NSFC","doi-asserted-by":"publisher","award":["82473775"],"award-info":[{"award-number":["82473775"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"NSFC","doi-asserted-by":"publisher","award":["82073690"],"award-info":[{"award-number":["82073690"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"NSFC","doi-asserted-by":"publisher","award":["82273774"],"award-info":[{"award-number":["82273774"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"NSFC","doi-asserted-by":"publisher","award":["82173676"],"award-info":[{"award-number":["82173676"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016359","name":"Zhongnan Hospital of Wuhan University","doi-asserted-by":"publisher","award":["ZNLH202201"],"award-info":[{"award-number":["ZNLH202201"]}],"id":[{"id":"10.13039\/501100016359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejmech.2025.118295","type":"journal-article","created":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:44:52Z","timestamp":1761493492000},"page":"118295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"P1","title":["The novel SIRT2-targeted PROTAC degraders as the efficient agents for the treatment of ovarian cancer"],"prefix":"10.1016","volume":"302","author":[{"given":"Dandan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihe","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chune","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Bing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118295_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2025.118295_bib2","first-page":"1","article-title":"Cancer statistics","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"Suppl 1","key":"10.1016\/j.ejmech.2025.118295_bib3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ijgo.13878","article-title":"Cancer of the ovary, fallopian tube, and peritoneum: 2021 update","volume":"155","author":"Berek","year":"2021","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.ejmech.2025.118295_bib4","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1186\/s12964-024-01880-8","article-title":"Alternative splicing in ovarian cancer","volume":"22","author":"Wei","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.ejmech.2025.118295_bib5","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12943-024-01967-3","article-title":"Drug resistance in ovarian cancer: from mechanism to clinical trial","volume":"23","author":"Wang","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2025.118295_bib6","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.ygyno.2018.06.022","article-title":"Sites of distant metastases and overall survival in ovarian cancer: a study of 1481 patients","volume":"150","author":"Deng","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118295_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242015066","article-title":"The roles of histone deacetylases in the regulation of ovarian cancer metastasis","volume":"24","author":"Xu","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.ejmech.2025.118295_bib8","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.ccell.2024.08.016","article-title":"Ovarian cancer metastasis : looking beyond the surface","volume":"42","author":"Bayraktar","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2025.118295_bib9","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3390\/biom14050585","article-title":"Oncogenic pathways and targeted therapies in ovarian cancer","volume":"14","author":"Lliberos","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejmech.2025.118295_bib10","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.semcdb.2017.01.007","article-title":"Poly(ADP-ribose) polymerase activity and inhibition in cancer","volume":"63","author":"Dulaney","year":"2017","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2025.118295_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2022.100049","article-title":"Homologous recombination repair deficiency: an overview for pathologists","volume":"36","author":"Doig","year":"2023","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ejmech.2025.118295_bib12","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.tranon.2017.09.006","article-title":"Downregulation of SIRT2 inhibits invasion of hepatocellular carcinoma by inhibiting energy metabolism","volume":"10","author":"Huang","year":"2017","journal-title":"Transl. Oncol"},{"key":"10.1016\/j.ejmech.2025.118295_bib13","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1002\/ijc.33118","article-title":"The role of SIRT2 in cancer: a novel therapeutic target","volume":"147","author":"Chen","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.118295_bib14","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.cmet.2020.07.008","article-title":"Sirt2 inhibition enhances metabolic fitness and effector functions of tumor-reactive T cells","volume":"32","author":"Hamaidi","year":"2020","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejmech.2025.118295_bib15","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ccr.2013.02.005","article-title":"Lysine-5 acetylation negatively regulates lactate dehydrogenase a and is decreased in pancreatic cancer","volume":"23","author":"Zhao","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2025.118295_bib16","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-022-01257-8","article-title":"The sirtuin family in health and disease","volume":"7","author":"Wu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ejmech.2025.118295_bib17","article-title":"Cancer the discovery of acyl thiourea derivatives as potent hydrophobic tagging degraders targeting SIRT2 for the treatment of ovarian cancer","author":"Wang","year":"2025","journal-title":"Chinese Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118295_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112981","article-title":"Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: recent progress and future challenges","volume":"210","author":"Zeng","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118295_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215716","article-title":"Proteolysis-targeting chimeras: a promising technique in cancer therapy for gaining insights into tumor development","volume":"539","author":"Lv","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2025.118295_bib20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","article-title":"Targeted protein degradation: mechanisms, strategies and application","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ejmech.2025.118295_bib21","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41573-019-0047-y","article-title":"Targeted protein degradation: expanding the toolbox","volume":"18","author":"Schapira","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118295_bib22","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.7150\/thno.92526","article-title":"Degraders in epigenetic therapy: PROTACs and beyond","volume":"14","author":"Dai","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2025.118295_bib23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1146\/annurev-cancerbio-030617-050430","article-title":"Proteolysis-targeting chimeras: harnessing the ubiquitin-proteasome system to induce degradation of specific target proteins","volume":"2","author":"Coleman","year":"2018","journal-title":"Annu. Rev. Cancer Biol."},{"key":"10.1016\/j.ejmech.2025.118295_bib24","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1021\/acschembio.1c00331","article-title":"Pharmacological advantage of SIRT2-selective versus pan-SIRT1-3 inhibitors","volume":"16","author":"Hong","year":"2021","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118295_bib25","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.1021\/jm049933m","article-title":"An in silico approach to discovering novel inhibitors of human sirtuin type 2","volume":"47","author":"Tervo","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118295_bib26","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1158\/0008-5472.CAN-05-3617","article-title":"Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes","volume":"66","author":"Heltweg","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118295_bib27","doi-asserted-by":"crossref","first-page":"945","DOI":"10.4155\/fmc.14.44","article-title":"Sirtuin inhibitors as anticancer agents","volume":"6","author":"Hu","year":"2014","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118295_bib28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejmech.2014.12.027","article-title":"Functionalized tetrahydro-1 H-pyrido[4,3-b]indoles: a novel chemotype with Sirtuin 2 inhibitory activity","volume":"92","author":"Yang","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118295_bib29","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/cmdc.201800391","article-title":"Direct comparison of SIRT2 inhibitors: potency, specificity, activity-dependent inhibition, and on-target anticancer activities","volume":"13","author":"Spiegelman","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.118295_bib30","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ccr.2008.03.004","article-title":"Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator","volume":"13","author":"Lain","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2025.118295_bib31","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1126\/science.1143780","article-title":"Sirtuin 2 inhibitors rescue a-synuclein\u2013mediated toxicity in models of parkinson's disease","volume":"317","author":"Outeiro","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.118295_bib32","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ccell.2016.02.007","article-title":"A SIRT2-selective inhibitor promotes c-Myc oncoprotein degradation and exhibits broad anticancer activity","volume":"29","author":"Jing","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2025.118295_bib33","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1021\/acs.jmedchem.9b00315","article-title":"Development of peptide-based Sirtuin defatty-acylase inhibitors identified by the fluorescence probe, SFP3, that can efficiently measure defatty-acylase activity of sirtuin","volume":"62","author":"Kawaguchi","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118295_bib34","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1021\/acsmedchemlett.0c00423","article-title":"Simultaneous inhibition of SIRT2 deacetylase and defatty-acylase activities via a PROTAC strategy","volume":"11","author":"Hong","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118295_bib35","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1021\/acs.jmedchem.6b01872","article-title":"Chemically induced degradation of Sirtuin 2 (Sirt2) by a proteolysis targeting chimera (PROTAC) based on Sirtuin rearranging ligands (SirReals)","volume":"61","author":"Schiedel","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118295_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115678","article-title":"Rational design and optimization of acylthioureas as novel potent influenza virus non-nucleoside polymerase inhibitors","volume":"259","author":"Liu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118295_bib37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3727\/096504013X13854886566598","article-title":"The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells","volume":"21","author":"Ueno","year":"2013","journal-title":"Oncol. Res."},{"key":"10.1016\/j.ejmech.2025.118295_bib38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.neo.2019.10.006","article-title":"Targeting histone deacetylase SIRT1 selectively eradicates EGFR TKI-resistant cancer stem cells via regulation of mitochondrial oxidative phosphorylation in lung adenocarcinoma","volume":"22","author":"Sun","year":"2020","journal-title":"Neoplasia"},{"key":"10.1016\/j.ejmech.2025.118295_bib39","doi-asserted-by":"crossref","first-page":"12206","DOI":"10.3390\/molecules171012206","article-title":"Discovery and validation of SIRT2 inhibitors based on tenovin-6: use of a 1H-NMR method to assess deacetylase activity","volume":"17","author":"Pirrie","year":"2012","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118295_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/cdd.2017.181","article-title":"Reviewing the future of the P53 field","volume":"25","author":"Levine","year":"2018","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejmech.2025.118295_bib41","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s13046-016-0461-5","article-title":"Sirtuins in metabolism, DNA repair and cancer","volume":"35","author":"Mei","year":"2016","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118295_bib42","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.118295_bib43","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.tcb.2023.10.003","article-title":"Mitochondrial regulation in stem cells","volume":"34","author":"Wang","year":"2024","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118295_bib44","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2184.2003.00266.x","article-title":"The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer","volume":"36","author":"Vermeulen","year":"2003","journal-title":"Cell Prolif."},{"key":"10.1016\/j.ejmech.2025.118295_bib45","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/978-1-60327-815-7_24","article-title":"Cell-cycle synchrony for analysis of S. pombe DNA replication","volume":"521","author":"Luche","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.118295_bib46","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0092-8674(01)00317-8","article-title":"Crystal structure of a SIR2 homolog-NAD complex","volume":"105","author":"Min","year":"2001","journal-title":"Cell."},{"key":"10.1016\/j.ejmech.2025.118295_bib47","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3892\/mmr.2014.2914","article-title":"Predic Ki67 is a promising molecular target in the diagnosis of cancer","volume":"11","author":"Li","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejmech.2025.118295_bib48","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.semcancer.2019.05.012","article-title":"Role of the PI3K\/AKT\/mTOR signaling pathway in ovarian cancer: biological and therapeutic significance","volume":"59","author":"Ediriweera","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejmech.2025.118295_bib49","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41568-018-0074-8","article-title":"mTOR signalling and cellular metabolism are mutual determinants in cancer","volume":"18","author":"Mossmann","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2025.118295_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2019.100961","article-title":"SIRT2: controversy and multiple roles in disease and physiology","volume":"55","author":"Wang","year":"2019","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.ejmech.2025.118295_bib51","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1083\/jcb.200707126","article-title":"The regulation of SIRT2 function by cyclin-dependent kinases affects cell motility","volume":"180","author":"Pandithage","year":"2008","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118295_bib52","doi-asserted-by":"crossref","first-page":"7439","DOI":"10.1111\/jcmm.15365","article-title":"SIRT2 suppresses expression of inflammatory factors via Hsp90-glucocorticoid receptor signalling","volume":"24","author":"Sun","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ejmech.2025.118295_bib53","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1101\/gad.1412706","article-title":"SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis","volume":"20","author":"Vaquero","year":"2006","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejmech.2025.118295_bib54","doi-asserted-by":"crossref","first-page":"6054","DOI":"10.1074\/jbc.M113.537266","article-title":"Sirt2 deacetylase is a novel AKT binding partner critical for AKT activation by insulin","volume":"289","author":"Ramakrishnan","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118295_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110155","article-title":"SIRT2 regulates mitochondrial dynamics and reprogramming via MEK1-ERK-DRP1 and AKT1-DRP1 axes","volume":"37","author":"Cha","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2025.118295_bib56","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s43018-023-00617-9","article-title":"Clinical and translational advances in ovarian cancer therapy","volume":"4","author":"Konstantinopoulos","year":"2023","journal-title":"Nat. Cancer"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425010608?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425010608?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T09:16:47Z","timestamp":1773307007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425010608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":56,"alternative-id":["S0223523425010608"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118295","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The novel SIRT2-targeted PROTAC degraders as the efficient agents for the treatment of ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118295","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118295"}}